XtalPi 2228.HK HK$11.25 at HKSE close 16 Feb 2026: AI outlook vs valuation

The 2228.HK stock closed at HK$11.25 on the HKSE on 16 Feb 2026 after a day high at HK$11.25. Investors are watching XtalPi Holdings Ltd (2228.HK) for its AI-driven drug discovery tools and automation services in China and overseas. The share trades near its 50-day average of HK$11.03 and sits below a year high of HK$15.12. This report links the latest price action to fundamentals, technicals, and model forecasts. We outline valuation, Meyka AI grade, and near-term targets for Hong Kong traders.

2228.HK stock: Price, volume and recent performance

XtalPi (2228.HK) closed at HK$11.25 after the Hong Kong session. Volume was 14599891.00 shares versus an average volume of 73178479.00. The one-day change was 0.81% and the stock opened at HK$11.20. The 50-day average is HK$11.03 and the 200-day average is HK$9.03. Year high and low are HK$15.12 and HK$3.85 respectively.

2228.HK stock: Business model and AI advantage

XtalPi Holdings Ltd develops AI and automation for drug discovery. The company serves clients across China, the United States, Europe, South Korea, and Japan. Its services cover target validation, hit identification, and lead optimisation for small molecules and biologics. The AI edge supports higher throughput and shorter timelines compared with traditional discovery routes.

2228.HK stock: Financials and valuation snapshot

At the current price XtalPi shows EPS of 1.05 and a reported PE of 10.68. Market cap stands near HKD 48240797441.00. Key ratios show high price-to-sales at 62.58 and a price-to-book of 5.33. Free cash flow per share is negative at -0.13 and operating cash flow per share is -0.11. The current ratio is strong at 9.69, reflecting a cash cushion.

2228.HK stock: Technicals and trading signals

The technical picture is mixed and bearish to neutral. RSI reads 42.86, below neutral but not oversold. MACD shows a negative histogram at -0.18. Bollinger Bands middle sits at HK$12.05 and lower at HK$10.55. On balance, momentum indicators suggest caution for short-term buyers while the 50-day average near HK$11.03 acts as support.

Meyka AI rates 2228.HK with a score out of 100 and forecast

Meyka AI rates 2228.HK with a score out of 100: 62.99 (Grade B, Suggestion HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects a quarterly price of HK$13.19, a yearly price of HK$10.73, and a three-year price of HK$14.86. The yearly projection implies a -4.62% downside versus the current HK$11.25. Forecasts are model-based projections and not guarantees.

2228.HK stock: Risks and opportunities for AI investors

Opportunity: XtalPi benefits from growing demand for AI drug discovery and partnerships with pharma. Risk: Valuation metrics show stretched price-to-sales and negative cash flow per share. Additional risks include long receivables cycles and execution on commercialization. Watch upcoming earnings and partnership updates for catalysts.

Final Thoughts

Key takeaways for 2228.HK stock after the HKSE close on 16 Feb 2026: XtalPi (2228.HK) trades at HK$11.25, near its 50-day average and well below a year high of HK$15.12. The business combines AI and automation for drug discovery, creating a clear growth narrative. Financials show profitability pressure with negative free cash flow per share at -0.13 but strong liquidity via a current ratio of 9.69. Meyka AI’s grade is 62.99 (Grade B, HOLD). Meyka AI’s forecast model projects a quarterly target of HK$13.19 (implied upside 17.24%) and a yearly target of HK$10.73 (implied downside -4.62%) relative to HK$11.25. Traders should weigh AI-driven growth against high valuation multiples and cash flow risks. Monitor the earnings announcement on 2026-03-27 and partnership news for near-term catalysts. For Hong Kong market participants, a pragmatic approach is to hold for operational proof points or use a staged entry with stop-loss discipline.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.